Analyst firms · Barclays · BROS

Barclays BROS price target and rating history

Dutch Bros Inc. (BROS) · Consumer Discretionary

Barclays rates Dutch Bros Inc. (BROS) Overweight with a $65 price target, as of its latest action on Oct 22, 2025. It has published 4 rating actions on BROS since October 2021, including 1 upgrade and 0 downgrades. Across 11 firms with a BROS price target in the last 12 months, the median target is $73.

Current rating
Overweight
Price target
$65
Median target, all firms
$73
Actions on BROS
4

Barclays price target on BROS

$70$55$4020222023202420252026
Barclays price target on BROS, each point a stated target, October 2021 to October 2025.

Every Barclays rating on BROS

How other firms rate BROS

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
StifelBuy$48Nov 9, 2026
RBC Capital MarketsSector Perform$46Oct 22, 2026
DA DavidsonBuy$60Sep 28, 2026
Seaport Research PartnersBuy$50Sep 16, 2026
Telsey Advisory GroupOutperform$74Jul 31, 2026
StephensOverweight$80Jul 17, 2026
OppenheimerOutperform$72May 1, 2026
BNP Paribas ExaneOutperform$73Mar 30, 2026
Wolfe ResearchOutperform$77Mar 9, 2026
Goldman SachsBuy$75Mar 2, 2026
CitigroupBuy$82Jan 26, 2026

Questions about Barclays and BROS

What is Barclays's price target for BROS?
Barclays's latest stated price target for Dutch Bros Inc. (BROS) is $65, from its action on Oct 22, 2025.
What is Barclays's rating on BROS?
Barclays rates BROS Overweight, a bullish rating, as of Oct 22, 2025.
When did Barclays last change its view on BROS?
On Oct 22, 2025, Barclays cuts its price target to $65 from $92, keeps Overweight.
How does Barclays's BROS target compare with other analysts?
Across 11 firms with a BROS price target in the last 12 months, the median target is $73.

More BROS rating histories

All Barclays ratingsBROS news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.